A study of an investigational medicine, NLY01, in people with multiple sclerosis.

Recruiting now. Registry record last updated July 17, 2026.

Who can join: Adults 18 to 60, have multiple sclerosis, BMI 27+.
What you take: NLY01, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Johns Hopkins UniversityDrug NLY01Class OtherSites 2 USEnrollment target 120

What this study is for

Primary condition: Multiple Sclerosis.

Full scientific study title: Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis.

Who can join

Age18 to 60SexAnyBMI27 or higher

Adults 18 to 60, have multiple sclerosis, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
Aged 18-60 years
Body mass index ≥27.0 kg/m2

Key exclusion criteria

No GLP-1RA or GIP/GLP-1 RA in past year; no known hypersensitivity to medication class
No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis
No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2
No chronic kidney disease (estimated glomerular filtration rate ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications\*, dipeptidyl peptidase IV inhibitors\*\*, or warfarin; current/active alcohol or illicit substance abuse
No concerns about candidacy of individual on part of person's neurologist or study team clinicians

Where this trial is enrolling

This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.

Find a site near you

Maryland1 site

Johns Hopkins University
Baltimore, Maryland
Margaret Vieira667-306-8153mvieira4@jh.edu

New York1 site

Mount Sinai School of Medicine
New York, New York
Susan Filomena212-241-4364susan.e.filomena@mssm.edu

Follow this trial

We email you if NCT07497399 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: April 28, 2026. Expected completion: January 2030. Last updated on ClinicalTrials.gov: July 17, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.